Please login to order a test.
Gynecologic Pap Test (Image-guided), Liquid-based Preparation and Herpes Simplex Virus (HSV) Types 1 and 2, NAA and Human Papillomavirus (HPV) High-risk DNA Detection With Reflex to HPV Genotypes 16 and 18
Liquid-based cytology evaluation and evaluation for the presence of high-risk HPV DNA sequences. If the cytology evaluation is within normal limits, and the initial screen is positive for high-risk HPV DNA types in aggregate, then the residual specimen will be tested individually for high-risk HPV genotypes 16 and 18. Testing for HSV type 1 and type 2.
Diagnose primary or metastatic neoplasm. Detect and type active HSV shedding. Diagnosis of sexually-transmitted HPV infection. The initial high-risk HPV test is used for types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68, without differentiation of the individual types. If the Pap evaluation is within normal limits and the initial HPV test is positive, then the residual specimen will be tested individually for high-risk HPV genotypes 16 and 18. This information, together with the physician's assessment of cytology history, other risk factors, and professional guidelines, may be used to guide patient management. The results of this test are not intended to prevent women from proceeding to colposcopy.
Failure to obtain adequate ectocervical, endocervical, or vaginal cell population is suboptimal for evaluation. Excessive use of lubricating jelly on the vaginal speculum will interfere with cytologic examination and may lead to unsatisfactory Pap results.
The use of the liquid-based cytology specimen for multiple tests may limit the volume available for Pap reprocessing or HPV testing. A negative result does not exclude the possibility of an HPV infection since very low levels of infection or sampling error may produce a false-negative result.
This test is intended for use as an aid in the diagnosis of herpes simplex virus (HSV) infections with active viral shedding; it also differentiates HSV-1 from HSV-2. Negative HSV NAA results indicate lack of viral shedding but do not confirm the absence of previous infection.
Image-guided liquid-based Pap test; nucleic acid amplification (NAA)
Cervical cells in liquid-based cytology transport
ThinPrep® vial or SurePath™ vial
A minimum volume cannot be determined for the ThinPrep® vial because it varies depending on the cellularity of the specimen. The entire SurePath™ specimen should arrive intact.
ThinPrep® Vial−Broom Only:
Broom-like collection technique: Obtain a sample from the cervix using a broom-like device by inserting the brush portion into the cervical os and then rotate the brush five times. Rinse the collection device in the PreservCyt® solution by pushing the brush into the bottom of the vial 10 times, forcing the bristles to bend apart to release the cervical material. As a final step, twirl the brush between the thumb and forefinger vigorously to release additional cellular material. Discard the collection device. Tighten the cap on the ThinPrep® vial so that the torque line on the cap passes the torque line on the vial.
SurePath™ Vial: When using the SurePath™ vial, the cervical broom must be used for specimen collection. Insert the broom into the cervical os and rotate five times. Place the broom head into the CytoRich™ preservative fluid in the SurePath™ collection vial. Tightly cap the vial.
Maintain liquid-based cytology specimens at room temperature. Pap processing must be performed within 21 days of collection. HPV testing must be performed within three months of collection. SurePath™ vial must be processed for testing within 21 days of collection for HPV. Liquid-based cytology specimens must be tested winthin seven days for HSV.
Causes for Rejection
Improper collection; inadequate specimen; improperly labeled specimen; specimen leaked in transit; quantity not sufficient for analysis; name discrepancies; specimen submitted on male patient; specimen submitted in vial that expired according to manufacturer's label; frozen specimen. For Pap: liquid-based cytology specimen more than 21 days old. For HPV: specimen more than three months old in ThinPrep® vial; specimen more than 21 days old in SurePath™ vial. For HSV: liquid-based cytology specimen more than seven days old.
Include date of birth, Social Security number (or other identification number), previous malignancy, drug therapy, radiation therapy, last menstrual period (LMP), postmenopausal patient (PMP), surgery (including surgical biopsies), exogenous hormones, abnormal vaginal bleeding, abnormal Pap results, IUD, and all other pertinent clinical information on the cytology test request form.
Note: In accordance with criteria established by CLIA, Pap smears will be referred for pathologist review if laboratory personnel suspect:
• Reactive or reparative cellular changes
• Atypical squamous or glandular cells of undetermined significance
• Cells in the premalignant or malignant category
In these cases, LabCorp will charge for the associated service. (Slides that are routinely reviewed by a pathologist for quality control purposes are not included.)
If ThinPrep® vials are QNS for the hybrid capture assay, then a test requiring a lower input volume will be automatically performed if there is sufficient volume to perform that assay. If the additional assay is performed, testing for HPV genotypes 16 and 18 will not be performed due to volume limitations.
HSV NAA is a single test that both detects the presence of HSV DNA and determines which type is present in the positive samples. There is no mechanism, therefore, for testing for HSV-1 without simultaneously testing for HSV-2.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|198325||Pap IG, HSV, HPV, rfx16/18||019018||.||11546-9|
|198325||Pap IG, HSV, HPV, rfx16/18||019030||.||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||019031||Patient Counseling Report||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||188036||HSV 1 NAA||16130-7|
|198325||Pap IG, HSV, HPV, rfx16/18||188037||HSV 2 NAA||16131-5|
|198325||Pap IG, HSV, HPV, rfx16/18||188038||HSV 1 and 2 Tracking||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||190109||Note:||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||190120||.||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||191107||Clinical history:||22636-5|
|198325||Pap IG, HSV, HPV, rfx16/18||191108||DIAGNOSIS:||22637-3|
|198325||Pap IG, HSV, HPV, rfx16/18||191109||Specimen adequacy:||19764-0|
|198325||Pap IG, HSV, HPV, rfx16/18||191110||Additional comment:||22638-1|
|198325||Pap IG, HSV, HPV, rfx16/18||191111||Recommendation:||19773-1|
|198325||Pap IG, HSV, HPV, rfx16/18||191112||Performed by:||19767-3|
|198325||Pap IG, HSV, HPV, rfx16/18||191113||Electronically signed by:||19769-9|
|198325||Pap IG, HSV, HPV, rfx16/18||191121||Test ordered:||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||191123||Maturation index:||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||191124||Amended report:||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||191125||Addendum:||22639-9|
|198325||Pap IG, HSV, HPV, rfx16/18||191128||QC reviewed by:||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||191129||Cytology history:||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||191139||Special procedure:||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||191144||QA comment:||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||191145||Diagnosis provided by:||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||191154||Source:||19763-2|
|198325||Pap IG, HSV, HPV, rfx16/18||191157||Pathologist provided ICD9:||52797-8|
|198325||Pap IG, HSV, HPV, rfx16/18||191160||Clinician provided ICD9:||52797-8|
|198325||Pap IG, HSV, HPV, rfx16/18||191166||Interpretation||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||191167||Photomicrograph||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||191169||Infection:||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||191170||Category:||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||191172||Adequacy:||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||191173||Recommendation:||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||191174||Clinician provided ICD10:||52797-8|
|198325||Pap IG, HSV, HPV, rfx16/18||191175||Pathologist provided ICD10:||52797-8|
|198325||Pap IG, HSV, HPV, rfx16/18||191179||Previous history:||N/A|
|198325||Pap IG, HSV, HPV, rfx16/18||507303||HPV, high-risk||30167-1|
|198325||Pap IG, HSV, HPV, rfx16/18||000000||Test Methodology:||47527-7|
|Reflex Table for HPV, high-risk|
|Order Code||Order Name||Result Code||Result Name||UofM||Result LOINC|
|Reflex 1||507405||HPV, low volume rfx||507405||HPV, low volume rfx||59420-0|
|Reflex Table for Test Methodology:|
|Order Code||Order Name||Result Code||Result Name||UofM||Result LOINC|
|Reflex 1||192555||Change IG Pap to LB Pap||000000||LBP CPT Code Automation||47527-7|